What are you searching for?

Sign in
Breaking News, Promotions & Moves

Zafgen Appoints Chief Business Officer

Brian McVeigh brings 25 years of pharmaceutical and biotech industry experience to the company

Zafgen, Inc. has appointed Brian McVeigh as chief business officer. He brings over 25 years of pharmaceutical and biotech industry experience including 15 years of extensive experience in buy-side and sell-side business development deal making and investment management to Zafgen’s executive leadership team.


“Brian is an accomplished executive and adds significant value to our executive leadership team, and we are thrilled to welcome him to Zafgen,” said Jeffrey Hatfield, chief executive officer of Zafgen, Inc. “His deal-making and investment management expertise will prove vital to our business development strategy and execution as Zafgen continues to grow and work towards developing medicines to treat patients with both rare and prevalent complex metabolic diseases, such as type 2 diabetes and Prader-Willi syndrome.”

Mr. McVeigh joins Zafgen following a 25-year career with GlaxoSmithKline (GSK) where he held multiple senior-level positions within the global Business Development, Finance, Marketing, Corporate and R&D organizations. During his 15-year tenure in the Business Development organization he personally led the assessment and negotiation of more than two-dozen significant transactions including the acquisitions of Sirtris Pharmaceuticals, Domantis Ltd. and Genelab Technologies, Inc. While with GSK he most recently served as the Vice President of Worldwide Business Development Transactions and Investment Management. 

“Zafgen is uniquely positioned to make important advances in the development of treatments for complex metabolic disorders which can make a meaningful difference in the lives of patients with unmet medical needs,” said Mr. McVeigh. “I’m very excited to be joining such an exceptional team and look forward to working with them to maximize the value of the MetAP2 platform by delivering returns to our investors and important new medicines to patients in need.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters